WattjesMPRoviraÀMillerD. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—Establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11: 597–606.
2.
McGuiganCCranerMGuadagnoJ. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosurg Psychiatry2016; 87: 117–125.
WattjesMPWijburgMTVennegoorA. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. Mult Scler2016; 22: 1174–1183.
7.
WijburgMTWitteBIVennegoorA. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry2016; 87: 1138–1145.
8.
WattjesMPVennegoorAMostertJ. Diagnosis of asymptomatic natalizumab-associated PML: Are we between a rock and a hard place?J Neurol2014; 261: 1139–1143.
9.
MassRPMuller-HansmaAHEsselinkRA. Drug-associated progressive multifocal leukoencephalopathy: A clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol2016; 263: 2004–2021.
10.
WarnkeCvon GeldernGMarkwerthP. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol2014; 76: 792–801.
11.
WarnkeCOlssonTHartungHP.PML: The dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci2015; 36(12): 799–801.
12.
CliffordDBYousryTAMajorEO.A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?Mult Scler. Epub ahead of print 27September2016. DOI: 10.1177/1352458516670735.
